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Review of the Effectiveness of Tissue Plasminogen Activator for the Treatment of Plastic Bronchitis 
 in Patients with Fontan Physiology 
Ruth Ferroni, BSN, RN, CCRN 
Otterbein University, Westerville, Ohio 
  Introduction 
Fontan physiology (or circulation) involves hooking up systemic venous return directly to the 
branch pulmonary artery(s) thus bypassing the right side of the heart. This is also referred to 
as “passive circulation” and forward blood flow through the lungs is accomplished by pressure 
gradients between the central venous circulation and the pulmonary vascular bed.  The 
etiology is unclear, however increased pulmonary venous pressures may contribute to 
affecting the respiratory epithelium and interruption of the bronchial mucosa causing 
proteinaceous material to leak and hypersecretion of mucus with resultant cast formation. 
Histology samples of patients with congenital heart disease reveal acellular casts with mucin 
and fibrin and the absence of Charcot –Leyden crystals . Patients with primary pulmonary 
diseases  reveal a combination of inflammatory casts, eosinophils, Charcot –Leyden crystals  
and mucin thought t o be due to chronic bronchial inflammation (Do, 2009; Goldberg, 2010; 
Singhal, 2013). See figure 1. 
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Signs and Symptoms 
Figure 2. 
Conclusion 
Plastic bronchitis is a condition characterized by the formation of bronchial casts ranging 
from small to large obstructions of the pulmonary airways.  Cast formation is intricate and  
resembles a plastic, rubbery model of the airway it obstructs. Its form was first described by  
Galen (A.D. 131-200). One of the patient populations at risk for developing this rare 
complication are those with single ventricle disease who are surgically corrected to Fontan 
physiology. It is a very abnormal type of circulation that is suspect in the development of 
plastic bronchitis.  The cellular composition of plastic bronchitis differs from the casts seen in 
patients with chronic respiratory diseases such as asthma  or lymphatic disorders of the lung 
and, as a result, complete airway obstruction may occur more quickly with a resultant life- 
threatening and possibly fatal event.    
Bronchial casts may also be seen in other disease states such as  sickle cell disease, 
metastatic lung tumors, bronchopulmonary aspergillosis, thalassemia alpha,  and inhalation 
injuries (Do,  Randhawa, Chin, Parsapour, & Nussbaum, 2012).  Tissue plasminogen activator 
in an aerosolized form has shown to be effective therapy in most cases.  The following 
information is an update on the adaptation of this therapy in the last 5 years. 
 
The most common presenting symptoms are cough 
and intermittent dyspnea  (Goldberg, Rychik, & 
Dodds, 2010).  The cough may be productive or non-
productive depending on the patient’s ability to 
expectorate casts.  Frequently, thick mucus is 
expectorated with a mucus plug consistency which 
can be deceiving as the mucus plugs may actually be 
fragments breaking away from the cast. Chest pain 
and fever are also reported but occurs more 
frequently in patients with pulmonary parenchymal 
disease.  Cardiac patients rarely exhibit  
a fever, and blood and sputum cultures are usually 
negative (Heath et al., 2011). Breath sounds may be 
diminished, coarse, and wheezing may be present.  
Chest x-ray reveals opacity and consolidated lung 
fields similar to pneumonia and, bronchoscopy or 
expectoration of a cast is the only reliable 
determinant of the diagnosis.  See figure 2. 
Figure 1 
Slide (a) reveals hypocellular fibrinous casts.  Slide (b) reveals inflammatory 
casts with eosinophils, Charcot-Leyden crystals and mucin. 
Copyright 2013 Hindawi Publishing Corporation. 
(a) Expectorated cast.  (b) Cast extracted during  
flexible bronchoscopy. 
Copyright 2013 Hindawi Publishing Corporation. 
  
 
Once the airway is stabilized, patients with congenital heart disease suffering from the rare 
complication of plastic bronchitis are first evaluated for circulatory efficiency.  A cardiac catheterization 
is performed to determine venous systemic and pulmonary pressures, development of collateral 
circulation in the lungs, narrow pulmonary vessels and evaluation of the Fontan circuit.  The Fontan 
conduit may be fenestrated to reduce systemic venous pressure; narrowed blood vessels may be 
stented open, collaterals closed with obstructive devices and the functioning cardiac valve and ventricle 
assessed for optimum performance. Fontan physiology, at its best outcome mimics chronic, low grade 
congestive heart failure. Every effort is made to decrease systemic venous pressures and optimize 
cardiac output (Goldberg, et al.,2010). However, there is no guarantee of successful prevention of a 
recurrence of plastic bronchitis.  If histology shows dilated lymphatics, thoracic duct ligation is also 
considered especially if the patient exhibits problems with pleural effusions. (Colanari, Quarti, Pozzi, 
Gasparini, Carloni, & de Benedictis, 2014) 
Pharmacological therapy interventions include systemic and inhaled corticosteroids, mucolytics such as 
acetylcysteine and dornase alpha, and fibrinolytics namely Urokinase and Alteplase.   
Tissue plasminogen activator (tPA) or Alteplase, is a serine protease that leads to localized fibrinolysis 
by converting plasminogen to plasmin. According to the literature topical application and nebulized tPA 
has been the most successful treatment without adverse effects in several case reports of children with 
congenital heart disease complicated by cast bronchitis. Brogan et al. (as cited by Do  et al., 2012) 
isolated and incubated a bronchial cast from a Fontan patient and topically applied saline, Urokinase 
and Alteplase.  The saline produced no effect, the Urokinase made the cast softer and, the sample 
treated with Alteplase, completely dissolved. See figure 3. 
 
Figure 3.  
 
The left picture shows cast fragments wedged in the upper and lower lobes.  
The picture on the right shows the effect of tPA application after 15 
minutes. Copyright 2012 American Academy of  Pediatrics 
Nursing Care 
  
The acute phase of illness requires care to be focused on protecting and maintaining a patent 
airway and preventing acute deterioration due to sudden obstruction.  Extreme occlusion may 
require high frequency ventilation with intermittent bronchoscopies performed to treat casts 
topically and safely remove them.  Once the airways are cleared, emphasis is placed on long term 
supportive care, and determining a medication regime that effectively prevents recurrence if 
possible.   
Patient and caregiver teaching are vitally important for patient safety and quality of life.    Common 
upper respiratory illnesses or worsening congestive heart failure symptoms may confound the signs 
and symptoms of plastic bronchitis especially if the cough is non-productive.   
Education regarding chest physiotherapy techniques, maintaining a consistent medication schedule 
and prompt notification of their physician and healthcare team cannot be over- emphasized since 
there has been no established pattern to the recurrence of cast formation.  Its onset may be sudden 
or develop over time.  Coordination with emergency medical services in the patient’s community 
promotes prompt transfer to a tertiary center familiar with the disease process and capable of 
treating acute airway issues.  Family caregivers must comprehend the need to intervene quickly 
when a cough and dyspnea develops by notifying their cardiologist as soon as the symptoms appear 
and information taught needs to be return demonstrated by the “teach back” method to the nurse. 
Close monitoring of a recurrence is essential.  Journals are helpful to parents and caregivers for 
tracking signs, symptoms, medication dosing and frequency, and the patient’s general state of 
health.  Important contact numbers should be listed in the front of the journal for easy access.  
Kunder et al. (2013) report one of the largest case 
studies of plastic bronchitis retrospectively reviewed 
which included eight patients with Fontan physiology 
in the cohort and state that: 
“the mechanism of cast formation remains unclear 
both for the inflammatory casts 
 associated with lung disease and the hypocellular 
casts associated with congenital heart 
 disease. Currently, data are limited regarding 
optimal treatment of plastic bronchitis, so  
the clinician must rely on individual anecdotal case 
reports to guide therapy. “ The occurrence rate  is 
estimated to be from 4 to 14%  with a poor 
prognosis . 
 Alteplase has been proven to effectively dissolve 
bronchial casts yet optimal dosing strategy and 
length of maintenance therapy remain unknown.  
Some patients have responded with just one dose 
during the acute phase while others require home 
nebulization every 6 hours for months after the 
initial hospitalization.  There have been no observed 
side effects with tPA yet the volume of patients 
reported in the literature is statistically too low to 
prove best outcomes or how to achieve best 
outcomes with a specific dosing regimen.  There is 
also a major concern regarding the expense of tPA 
therapy and the reluctance of third party payers to 
cover the cost so determining the amount required 
for minimal efficient dosing facilitates better 
insurance coverage of the treatment options for 
these patients.  
An international plastic bronchitis registry to collect 
data on patients has been established to hopefully 
resolve questions about the pathophysiology of the 
disease and the most effective treatment. 
(www.clinicaltrials.gov, NCT0166398)  
Additional Resources 
Pathophysiology 
